FDA clears Lilly’s Retevmo for RET-positive lung, thyroid ca...

Eli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting the go-ahead from the FDA for RET inhibitor Retevmo.

AZ/Merck & Co's ovarian cancer drug gets wider US licence

AstraZeneca and Merck & Co have hit back at their rival GlaxoSmithKline after the FDA allowed Lynparza to be used in a wider group of ovarian cancer patients when combined with Roche’s

Concerns over BMS and Celgene merger payout as FDA extends d...

Bristol-Myers Squibb’s risky three-drug bet with former shareholders in Celgene is still on – but it could be a close-run thing after the FDA extended the review of a cancer cell therapy cl

Menarini bags blood cancer drug with $677M Stemline acquisit...

CHMP backs BMS’ first-in-class anaemia drug Reblozyl